Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17725812 | 0.88 | HSD17B10 (0.40) | HSD17B10NR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL5431463 | 0.86 | CTSK (0.39) | NR1H2CHRM2CHRM1CHRM3TSHR | |
| SCHEMBL22644358 | 0.86 | CTSK (0.39) | NR1H2CHRM2CHRM1CHRM3TSHR | |
| SCHEMBL25866969 | 0.86 | CTSK (0.39) | NR1H2CHRM2CHRM1CHRM3TSHR | |
| SCHEMBL9383049 | 0.86 | CTSK (0.39) | NR1H2CHRM2CHRM1CHRM3TSHR | |
| SCHEMBL5431465 | 0.86 | CTSK (0.39) | NR1H2CHRM2CHRM1CHRM3TSHR | |
| SCHEMBL25124204 | 0.84 | HSD17B10 (0.43) | HSD17B10CHRM2CHRM1CHRM3MEN1 | |
| SCHEMBL26405902 | 0.83 | HSD17B10 (0.45) | HSD17B10NR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL344752 | 0.80 | TSHR (0.56) | HSD17B10NR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL271429 | 0.80 | TSHR (0.56) | HSD17B10NR1H2CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230406851-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2023-12-21 | — | — | US | disclosed |
| EP-3998267-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | Bellus Health Cough Inc. (CA) | 2022-05-18 | — | — | EP | disclosed |
| US-20220062290-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2022-03-03 | — | — | US | disclosed |
| US-20220062290-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2022-03-03 | — | — | US | disclosed |
| EP-3381917-B1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | BELLUS HEALTH COUGH INC (CA) | 2021-09-08 | — | — | EP | disclosed |
| EP-3381917-B1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | BELLUS HEALTH COUGH INC (CA) | 2021-09-08 | — | — | EP | disclosed |
| US-20210228588-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2021-07-29 | — | — | US | disclosed |
| US-20210228588-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2021-07-29 | — | — | US | disclosed |
| CN-107485612-B | Imidazopyridine compounds and uses thereof | 尼奥迈德研究所 | 2021-03-30 | — | — | CN | disclosed |
| US-20200390779-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2020-12-17 | — | — | US | disclosed |
| US-20170143730-A1 | Imidazopyridine Compounds and Uses Thereof | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2017-05-25 | — | — | US | disclosed |
| US-20170143730-A1 | Imidazopyridine Compounds and Uses Thereof | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2017-05-25 | — | — | US | disclosed |
| US-20170143730-A1 | Imidazopyridine Compounds and Uses Thereof | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2017-05-25 | — | — | US | disclosed |
| US-9598409-B2 | Imidazopyridine compounds and uses thereof | NEOMED INSTITUTE (CA) | 2017-03-21 | — | — | US | disclosed |
| US-9598409-B2 | Imidazopyridine compounds and uses thereof | NEOMED INSTITUTE (CA) | 2017-03-21 | — | — | US | disclosed |
| US-9598409-B2 | Imidazopyridine compounds and uses thereof | NEOMED INSTITUTE (CA) | 2017-03-21 | — | — | US | disclosed |
| US-20150361078-A1 | Imidazopyridine Compounds and Uses Thereof | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2015-12-17 | — | — | US | disclosed |
| US-20150361078-A1 | Imidazopyridine Compounds and Uses Thereof | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2015-12-17 | — | — | US | disclosed |
| US-20150361078-A1 | Imidazopyridine Compounds and Uses Thereof | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2015-12-17 | — | — | US | disclosed |
| WO-2014117274-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | NEOMED INSTITUTE (CA) | 2014-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406851-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | NISCH, ABL1, PAICS | HSD17B10 4442/4885NR1H2 4746/4885CHRM2 2061/4885 |
| US-20200390779-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | NISCH, ABL1, PAICS | HSD17B10 4442/4885NR1H2 4746/4885CHRM2 2061/4885 |
| US-20150361078-A1 | Imidazopyridine Compounds and Uses Thereof | NISCH, ABL1, PAICS | HSD17B10 4442/4885NR1H2 4746/4885CHRM2 2061/4885 |
| US-20220062290-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | NISCH, ABL1, PAICS | HSD17B10 4442/4885NR1H2 4746/4885CHRM2 2061/4885 |
| US-20170143730-A1 | Imidazopyridine Compounds and Uses Thereof | NISCH, ABL1, PAICS | HSD17B10 4442/4885NR1H2 4746/4885CHRM2 2061/4885 |
| US-20210228588-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | NISCH, ABL1, PAICS | HSD17B10 4442/4885NR1H2 4746/4885CHRM2 2061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.